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Abstract
A dose of 200 mg 3-weekly of pembrolizumab was approved by the Food and Drug
Administration (FDA) as treatment for advanced non-small cell lung cancer (NSCLC)
without oncogenic drivers. This is despite evidence showing no difference in efficacy
with 2 mg/kg. Our study aimed to assess the efficacy of a lower fixed dose of 100 mg,
which is closer to 2 mg/kg weight-based dose in an average-sized Asian patient. All
patients receiving pembrolizumab for advanced NSCLC from January 2016 to March
2020 in National University Hospital, Singapore, were included in this retrospective
observational study. The effect of pembrolizumab 100 mg (Pem100) vs 200 mg
(Pem200) upon survival outcomes, toxicity and cost were examined. One hundred four-
teen patients received pembrolizumab. Sixty-five (57%) and 49 (43%) received Pem100
and Pem200, respectively. There was no difference in progression-free survival (PFS)
and overall survival (OS) between Pem100 vs Pem200 as a single agent (PFS: 6.8 vs
4.2 months, hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.36-1.46, P = .36;
9 month OS: 58% vs 63%, HR 1.08, 95% CI 0.48-2.41, P = .86) and when combined
with chemotherapy (9-month PFS: 60% vs 50%, HR0.84, 95% CI 0.34-2.08, P = .71; 9-
month OS: 85% vs 58%, HR 0.27, 95% CI 0.062-1.20, P = .09). No significant difference
in response rate or ≥G3 immune-related toxicities between Pem100 and Pem200 was
observed. A cost minimisation analysis evaluating the degree of cost savings related to
drug costs estimated a within study cost saving of SGD4,290,912 and cost saving per
patient of SGD39,942 in the Pem100 group. A 100 mg of pembrolizumab appears to be
effective with reduction in cost. A randomised trial should be done to investigate a
lower dose of pembrolizumab.
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1 | INTRODUCTION
Worldwide, lung cancer is the most common cancer and leading cause
of cancer death.1 Cancer immunology has enabled the development
of immune modulators that have markedly altered the treatment land-
scape for patients with advanced non-small cell lung cancers (NSCLC)
that do not harbour oncogenic drivers.2
Pembrolizumab is a fully humanised immunoglobulin G4 mono-
clonal antibody directed against the programmed cell death protein
1 (PD-1) receptor, antagonising the interaction between itself and its
ligand, resulting in anti-tumour immune response.3,4,5 Since the Food
and Drug Administration (FDA) approval of pembrolizumab in 20156
in pre-treated NSCLC,7,8,9,10 pembrolizumab has rapidly transited to
standard of care first line treatment as a monotherapy11,12,13 or with
chemotherapy14,15,16,17 for NSCLC with no oncogenic drivers.
In the landmark KEYNOTE-001, an ex vivo pharmacokinetics
study of PD-1 receptor saturation found complete peripheral target
engagement at 1 mg/kg. In the initial dose escalation cohort, durable
anti-tumour activity across all patient cohorts from 1-10 mg/kg once
every 3 weeks was observed.18 The subsequent expansion cohorts
demonstrated that the efficacy of 2 mg/kg 3-weekly was similar to
higher dose 10 mg/kg 2-weekly regimen but a dose of <2 mg/kg was
not examined.7,9,12,19
Despite the pharmacokinetics profile showing PD-1 receptor sat-
uration at 1 mg/kg and clinical efficacy at 2 mg/kg, a flat dose of
200 mg 3-weekly was used in Phase III trials leading to the FDA
approval of 200 mg every 3 weeks.14,15,16,17 More recently, the FDA
granted accelerated approval of a new dosing regimen of 400 mg
every 6 weeks.6
Goldstein et al performed an economic analysis comparing the
FDA approved fixed dosing and personalised dosing at 2 mg/kg and
estimated a cost saving of USD$0.8 billion annually to the United
States healthcare system based on an average weight of 75 kg in an
American adult patient.20,21,22,23 The average weight of an Asian
patient is 60 kg giving an average personalised dose of 120 mg in this
population.24
Given the lack of benefit demonstrated by pembrolizumab at
doses above 2 mg/kg, the lower weight of Asian patients, economic
benefits of a lower dose and packaging of pembrolizumab in 100 mg
vials, a fixed dose of 100 mg pembrolizumab required evaluation in an
Asian population.
Using a retrospective observational design, our study aimed to
evaluate the efficacy of low-dose pembrolizumab (Pem100) compared
with standard-dose pembrolizumab (Pem200) in the treatment of
NSCLC.
2 | METHODS
2.1 | Patients and treatment
All patients receiving palliative intent pembrolizumab for advanced
NSCLC with or without chemotherapy between January 2016 and
March 2020 in an academic tertiary medical centre (National Univer-
sity Hospital, Singapore) were identified retrospectively from the
pharmaceutical database. Baseline patient demographics, tumour and
treatment characteristics were extracted from the electronic medical
records.
The dose of 100 mg was routinely delivered based on an approxi-
mate 2 mg/kg weight-based dose, for patients who did not have an
adequate financial reimbursement plan or based on physician's prefer-
ence. Local protocols continue treatment until disease progression,
unacceptable toxicities, death, patient's decision to stop treatment or
after a total of 35 cycles of pembrolizumab although some patients
who remained progression free after 35 cycles continued treatment.
2.2 | Response evaluation
Chest and/or abdominal CT scans were performed by clinicians every
8-12 weeks as part of routine clinical care, to evaluate patient's
response and assess for disease progression. The scans were evalu-
ated by investigators retrospectively. In line with the KEYNOTE stud-
ies efficacy analysis was examined only in patients without an
oncogenic driver mutation. A systemic response to pembrolizumab
was measured by standard Response Evaluation Criteria in Solid
Tumours (V.1.1).25 The best response was classified as progressive
disease (PD), stable disease (SD), partial response (PR) and complete
response. Progression-free survival (PFS) was measured from time of
initiation of drug to disease progression by RECIST or death due to
any cause. Overall survival (OS) was measured from time of initiation
of drug to death. Safety analysis examined the incidence of ≥ Grade
3 immune-related adverse events (irAEs) and adverse events (AEs) as
recorded by clinicians.
2.3 | IHC of PDL1
The PD-L1 IHC 22C3 pharmDx assay26,27 was used to assess PD-
L1 expression in formalin-fixed tumour samples obtained at the
What's new?
Pembrolizumab, a monoclonal antibody directed against the
PD-1 receptor, has received FDA approval for the treatment
of lung cancer at a fixed dose of 200 mg every 3 weeks.
However, doses above 2 mg/kg show a lack of benefit, calling
for further evaluation in Asian populations. This retrospective
observational study demonstrates the efficacy of a lower
fixed dose of pembrolizumab (100 mg every 3 weeks) com-
pared with standard-dose pembrolizumab. The results also
confirm the clinical activity of pembrolizumab at a lower dose
than 2 mg/kg every 3 weeks, which could provide consider-
able cost savings to patients and the health system.
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time of diagnosis of metastatic disease. PD-L1 clone 22C3 is from Dako
and stained on Roche Ventana Benchmark Ultra ISH/IHC autostainer
with Optiview Polymer Detection Kit. Interpretation of PD-L1 expres-
sion is based on the interpretation guide provided by Dako and was
characterised according to tumour proportion score (TPS).28
2.4 | Statistical and economic analysis
Differences in the baseline characteristics of patients receiving
Pem100 and Pem200 were evaluated using the Fisher's exact test.
Survival analyses were performed using the Kaplan-Meier method
and were compared using a log-rank test. Multi-variable Cox propor-
tional hazard regression models were used to assess the relationship
between baseline factors (including treatment) and survival. A P-value
of <.05 was considered statistically significant. All statistical tests
were two-sided and were performed using IBM SPSS Statistics
Version 22.
Based on an acceptance of non-inferior survival and toxicity
outcomes, a limited economic evaluation was carried out using a
cost-minimisation approach.29 This assessed the monetary savings
available from the use of Pem100 instead of Pem200 based on the
total and median cycles of pembrolizumab received by the study
population and the price of a 100 mg vial of pembrolizumab.
Sensitivity analysis considered the potential savings within the study
population if all patients and if patients weighing ≤100 kg (translat-
ing to a dose of at least 1 mg/kg) were to receive Pem100. Given the
identical regimens and observed clinical outcomes, all other costs
were assumed to remain constant.
3 | RESULTS
3.1 | Patient characteristics
One hundred fourteen patients received pembrolizumab for advanced
NSCLC from January 2016 to March 2020 in National University Hospital
(Singapore). Baseline demographics are shown in Table 1. Median age was
67.4 years (range, 28.4-92.2). A majority of patients were male (86, 75%),
Chinese (83, 73%), former/current smokers (81, 71%) and had an ECOG
status of 0/1 (88, 77%). The average weight was 59 kg (range, 31-103).
Tumour characteristics are summarised in Table 2. Eighty-one
(71%), 13 (11%) and 16 (14%) of patients had adenocarcinoma, squa-
mous cell carcinoma and poorly differentiated carcinoma, respectively.
Sixty-three (55%), 31 (27%) and 16 (14%) of patients had a PDL1-TPS
score of ≥50%, 1%-49% and 0%, respectively. Pembrolizumab was
prescribed as first-line therapy in 91 (80%), second-line therapy in
15 (13%), third line and beyond in 8 (7%) patients. Sixty-five (57%)
and 49 (43%) received pembrolizumab as monotherapy and combined
with chemotherapy, respectively.
3.2 | Pembrolizumab dosing
A majority of patients (65/114, 57%) received pembrolizumab at a
starting dose of 100 mg 3-weekly (Pem100). The remaining 43%
received pembrolizumab at a starting dose of 200 mg 3-weekly
(Pem200). The two cohorts were matched in terms of gender,
smoking history, ECOG status and histological subtype (P > .05).
Patients in the Pem200 group were younger (median age 60.5 vs
TABLE 1 Baseline demographics
Total (n = 114) Pem 200 (n = 49) Pem 100 (n = 65) P values
Age at diagnosis (median, range) 67.4 (28.4-92.2) 60.5 (28.4-80.0) 69.9 (42.8-92.2) <.001
Weight (median, range) 59 (31-103) 59 (37-103) 59 (31-101) .245
Sex Male 86 (75%) 41 (84%) 45 (69%) .084
Female 28 (25%) 8 (16%) 20 (31%)
Ethnicity Chinese 83 (73%) 32 (65%) 51 (78%) .006
Malay 17 (15%) 6 (12%) 11 (17%)
Indian 1 (1%) 0 (0%) 1 (2%)
Others 13 (11%) 11 (23%) 2 (3%)
Smoking history Current/ex-smoker 81 (71%) 32 (65%) 49 (75%) .298
Never smoker 33 (29%) 17 (35%) 16 (25%)
Performance status 0-1 88 (77%) 42 (86%) 46 (71%) .053
2 11 (10%) 1 (2%) 10 (15%)
≥3 14 (12%) 6 (12%) 8 (12%)
Unknown 1 (1%) 0 (0%) 1 (2%)
Renal function CrCl <30 2 (2%) 1 (2%) 1 (2%) <.001
CrCl 30 to <40 6 (5%) 0 (0%) 6 (9%)
CrCl 40 to <50 7 (6%) 2 (4%) 5 (8%)
CrCl 50 to <60 23 (20%) 3 (6%) 20 (31%)
CrCl >60 76 (67%) 43 (88%) 33 (51%)
Hepatic function Liver dysfunction 6 (5%) 3 (6%) 3 (5%) .519
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69.9, P < .001), with worse renal function (P < .001) compared to
those in the Pem100 group (Table 1).
Significantly more patients in Pem100 had a PD-L1 (TPS) score of
≥50% (68% vs 39%, P = .005) and received pembrolizumab as a mon-
otherapy (74% vs 35%, P < .001). Median dose received was 2.87 mg/
kg vs 1.85 mg/kg (P < .001) and a <2 mg/kg dose was received by 4%
vs 62% (P < .001) in the Pem200 and Pem100, respectively.
3.3 | Outcomes
3.3.1 | Survival
Ten patients with oncogenic driven NSCLC who received
pembrolizumab were excluded from the analysis. Median duration of
follow-up was 14.8 months.
The median PFS of Pem100 vs Pem200 as a single agent was not
statistically significant at 6.8 vs 4.2 months (HR 0.60, 95% CI 0.30-
1.22, P = .16) (Figure 1A ). PFS for Pem100 and Pem200 did not differ
in all subgroups examined (Figure 2). Median OS was 14.3 vs
19.8 months (HR 1.08, 95% CI 0.48-2.41, P = .86) for Pem100 vs
Pem200, respectively (Figure 1B). Median PFS and OS of
pembrolizumab <2 vs ≥2 mg/kg as a single agent did not differ (PFS:
8.9 vs 5.3 months HR 0.98, 95% CI 0.52-1.85, P = .96; OS 14.7 vs
13.5 months, HR 1.04, 95% CI 0.51-2.13, P = .91) (Figure 3A,B).
Where Pembrolizumab was delivered with chemotherapy, the
median PFS was not reached in the Pem100 cohort vs 11.9 months
(HR 0.84, 95% CI 0.34-2.08, P = .71) for the Pem200 cohort. Median
OS was not reached in either group. Nine-month OS with chemother-
apy was 85% vs 58% (HR 0.27, 95% CI 0.062-1.20, P = .09) for
Pem100 and Pem200, respectively.
3.4 | Response rates
We analysed the response rates (RRs) of 88 patients who received
pembrolizumab in the first line setting. Forty-six received
pembrolizumab as a single agent and 42 received pembrolizumab
combined with chemotherapy. RR and disease control rate (DCR)
were numerically higher in patients who received single agent
Pem100 compared to Pem200 (RR: 45.5% vs 23.1%, P = .20, CBR:
72.2% vs 53.8%, P = .30). This was however not statistically signifi-
cant. Similarly, when pembrolizumab was combined with chemother-
apy, there was also no difference in the RR and DCR (RR 46.1% vs
48.3%, P = 1.00, CBR 92% vs 86, P = 1.00 for Pem100 and Pem200,
respectively) (Table 3).
3.5 | Toxicities
Eighteen patients discontinued treatment due to toxicities. There was
no dose relationship between pembrolizumab and serious irAEs. The
rates of G3 or more irAEs between Pem100 and Pem200 were
observed to be 17% vs 22%, P = .5.
TABLE 2 Tumour and treatment characteristics
Total (n = 114) Pem200 (n = 49) Pem100 (n = 65) P values
Histological subtype Adenocarcinoma 81 (71%) 37 (76%) 44 (68%) .553
Squamous cell carcinoma 13 (11%) 7 (14%) 6 (9%)
Poorly differentiated 16 (14%) 5 (10%) 11 (17%)
Others 4a (4%) 0 (0%) 4 (6%)
PD-L1 TPS score 0% 16 (14%) 11 (22%) 5 (8%) .005
1%-49% 31 (27%) 18 (37%) 13 (20%)
≥50% 63 (55%) 19 (39%) 44 (68%)
Unknown 4 (4%) 1 (2%) 3 (4%)
Driver mutation status EGFR positive 7 (6%) 2 (4%) 5 (8%) 1.00
ALK positive 1 (1%) 0 (0%) 1 (2%)
ROS positive 2 (2%) 2 (4%) 0 (0%)
Line of treatment in palliative setting First line 91 (80%) 43 (88%) 48 (74%) .223
Second line 15 (13%) 4 (8%) 11 (17%)
Third line and beyond 8 (7%) 2 (4%) 6 (9%)
Partner drug, n (%) Monotherapy 65 (57%) 17 (35%) 48 (74%) <.001
Combined with chemotherapy 49b (43%) 32 (65%) 17 (26%)
Dose/kg of pembrolizumab Median dose received (range) 2.27 (1.24-4.98) 2.87 (1.94-4.98) 1.85 (1.24-3.2) <.001
Number of patients who received
<2 mg/kg
42 2 (4%) 40 (62%) <.001
aAdenosquamous (n = 1), epithelioma-like (1), pleomorphic (1), unknown (1).
bChemotherapy combination—carboplatin/pemetrexed (n = 44), carboplatin/paclitaxel (n = 3), carboplatin/abraxane (n = 2).
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F IGURE 1 A, Progression free survival of single agent Pem100 and Pem200. B, Overall survival of single agent Pem100 and Pem200 [Color figure
can be viewed at wileyonlinelibrary.com]
F IGURE 2 Multivariable cox-proportional hazards model for progression free survival of patients receiving pembrolizumab monotherapy [Color
figure can be viewed at wileyonlinelibrary.com]
3.6 | Cost analysis
A 100 mg vial of pembrolizumab costs SGD5706 (1 SGD ≈ 0.72 USD) in
Singapore. The total number of cycles received by all the patients in our
study is 1243, with 752 vs 491 cycles delivered in the Pem100 and Pem200
group, respectively. The median number of cycles was 7 (range, 1-70 cycles).
We estimated a total cost saving in the study population of SGD
4,290 912 based on the total number of cycles of pembrolizumab received
by the Pem100 group. Assuming Pem100 was used instead of Pem200
across the entire study population, the cost minimisation analysis demon-
strates a cost saving of SGD 7, 092, 558 and SGD 39942 per patient
based on the median number of cycles received in our study population. A
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F IGURE 3 A, Progression free survival of single agent pembrolizumab ≥2mg/kg and pembrolizumab <2mg/kg. B, Overall survival of single
agent pembrolizumab ≥2mg/kg and pembrolizumab <2mg/kg [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 3 Response outcomes of Pem100 vs Pem200 in first line setting
Single agent (n = 46) Combined with chemotherapy (n = 42)
Pem 100 (n = 33) Pem 200 (n = 13) P value Pem 100 (n = 13) Pem 200 (n = 29) P value
Progressive disease 8 (24%) 4 (31%) 1 (7%) 2 (7%)
Stable disease 9 (27%) 4 (31%) 6 (46%) 11 (38%)
Partial response 14 (42%) 3 (23%) 5 (38%) 14 (48%)
Complete response 1 (3%) 0 (0%) 1 (8%) 0 (0%)
Not evaluable 1 (3%) 2 (15%) 0 (0%) 2 (7%)
Response rate, n (%) 15 (45.5%) 3 (23.1%) .20 6 (46.1%) 14 (48.3%) 1.00
Disease control ratea, n (%) 24 (72.7%) 7 (53.8%) .30 12 (92%) 25 (86%) 1.00
aDisease control rate = stable disease + partial response + complete response.
further sensitivity analysis of Pem100 in patients weighing ≤100 kg dem-
onstrates a total cost savings of SGD 70065706.
4 | DISCUSSION
To our knowledge, our study represents the largest cohort to date in
which the efficacy of a lower fixed dose of 100 mg pembrolizumab
given 3-weekly is demonstrated.30 We also confirm the clinical activity
of pembrolizumab at a dose lower than 2 mg/kg 3-weekly.
Many studies have demonstrated that dose selection of immune check-
point inhibitors can be challenging with non-linear relationships between
dose and clinical outcomes. A pharmacokinetic analysis of doses of 200 mg
and 2 mg/kg showed similar exposure distributions with no advantage to
either dosing approach.31 Similarly, modelling of data from KEYNOTE-001
demonstrated that pembrolizumab kinetics are linear above 0.3 mg/kg and
there is 95% trough target engagement with dosing at 0.8 mg/kg 3-weekly
with saturation of PD-L1 receptor at a dose ≥1 mg/kg.32-34 Indeed, the
expansion cohort of KEYNOTE-001 demonstrated clinical efficacy at its low-
est evaluated dose of 2 mg/kg.19 Other dosing strategies at <2 mg/kg, dose
banding and increasing the interval of dosing have also demonstrated effi-
cacy.35,36 The CanadianAgency ofDrug and Technologies used a pharmaco-
kinetic model demonstrating adequate trough PD-1 target engagement of
96% for thoseweighing 150 kg receiving the 400 mg 6-weekly.37-39
In our study, the median patient weight was 59 kg. More than half of
our patients received a fixed dose of 100 mg, with a median dose of
1.85 mg/kg (range, 1.24-3.2 mg/kg 3-weekly) in the Pem100 group. This
was close to a dose of 2 mg/kg and could explain why we did not see a
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difference in the efficacy in Pem100 vs Pem200. No efficacy difference
between <2 and ≥ 2 mg/kg 3-weekly. In fact, survival results numerically
favoured <2mg/kg.
A fixed 100 mg dose of pembrolizumab appears to be cost efficient
and logistically feasible, requiring a complete vial per patient. Goldstein
et al demonstrated huge cost savings to the US healthcare system by
using a personalised dosing of 2 mg/kg.20 In fact, the economic impact
may be underestimated given the rising price of pembrolizumab.40
Despite this, weight-based dosing is not widely adopted. With
pembrolizumab packaged and sold as 100 mg vials by pharmaceutical
companies in many countries, weight-based dosing is logistically chal-
lenging. Furthermore, vial sharing is not widely adopted as vial misuse,
including unsafe handling, has led to vial contamination and risks of
bloodborne illness transmission between patients.21 The results of our
study provide a practical solution and eliminate the need for vial sharing.
Our study has its limitations. Despite the attractiveness of dosing
pembrolizumab at a 100 mg fixed dose 3-weekly or 200 mg6-weekly, fixed
dosing must be interpreted with caution in a heavier patient. None of the
patients in our study received a dose a <1mg/kg, with a dose range of 1.24
to 1.99 mg/kg for patients who received <2 mg/kg pembrolizumab. Cross-
trial comparisons of our study against the other KEYNOTE studies are not
valid given the different nature of the study design and heterogenicity of
our study population. Moreover, the retrospective nature of the study, dif-
fering baseline characteristics and limited sample size does not allow for
valid efficacy comparison among different dosing strategies. Also, there are
some imbalances in our study groups with more patients in the Pem100
group having a PDL1 TPS score ≥50%. In a non-randomised setting, this
may result in selection bias, potentially accounting for the favourable out-
come observed here for Pem100. However, most of these patients also
received pembrolizumab as monotherapy and the subgroup analysis of PFS
based on PDL1 expression in patients receiving pembrolizumab mon-
otherapy did not differ. Thirdly, the relatively limited sample size limits the
power of our study to demonstrate a statistically significant difference.
Finally, given no difference was identified in the clinical outcomes of the
two regimens a cost minimisation analysis was used to examine the cost
saving provided by Pem100. This was not planned a priori and simply pro-
vides an indication of possible savings. The costs assessed are only those of
the drug and do not include regimen related costs such as drug administra-
tion, premedication, clinic visits, subsequent therapy and AE management.
Based on the study outcomes these costs are not anticipated to vary; how-
ever, further formal assessment of the cost-utility of Pem100 should be
considered alongside any future randomised study.
Despite these limitations, our study is the first to suggest clinical
efficacy of pembrolizumab at a fixed dose of 100 mg 3-weekly. This
lower dose could be efficacious and provide considerable cost savings
to both patients and the health system more widely. Such savings
could be redistributed to other health needs.41-43
5 | CONCLUSION
In our study, pembrolizumab had efficacy at a dose of 100 mg
3-weekly. With the expanding role of immune checkpoint inhibitors in
many tumour types, the principles and solutions discussed here will
be highly relevant to oncologists, policymakers and patients alike. A
randomised prospective trial is now required to further investigate the
role and cost-effectiveness of lower-fixed dosing of pembrolizumab at
100 mg 3-weekly or 200 mg 6-weekly.
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